Close Menu

Hsien-Hsien Lei reports that three companies, Neuromark, Psynomics, and SureGene, are now offering genetic tests for mental illness variants. Neuromark’s Mark-C test will test for markers GRIK2 and GRIA3, which are believed to increase the risk of suicidal thoughts in people on Celexa. Psynome tests for two mutations in the GRK3 gene associated with bipolar disorder. SureGene's AssureGene test will look at genes associated with patients at risk of developing psychosis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.